Comparative Pharmacology
Head-to-head clinical analysis: CLARITHROMYCIN versus E MYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITHROMYCIN versus E MYCIN E.
CLARITHROMYCIN vs E-MYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the 23S rRNA component, blocking peptide chain elongation and exerting bacteriostatic or bactericidal effects depending on concentration and organism.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
250-500 mg orally twice daily for 7-14 days; for MAC infection: 500 mg twice daily.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in adults with normal renal function; prolonged to 8-12 hours in moderate to severe renal impairment; clinical context: allows twice-daily dosing; active metabolite (14-hydroxyclarithromycin) half-life similar.
Clinical Note
moderateClarithromycin + Levofloxacin
"Clarithromycin may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateClarithromycin + Norfloxacin
"Clarithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClarithromycin + Gemifloxacin
"Clarithromycin may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateClarithromycin + Haloperidol
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Renal: approximately 30-40% unchanged; biliary/fecal: approximately 40-50% as metabolites; total renal clearance accounts for about 30-40% of dose; hepatic metabolism contributes to elimination; dose adjustment required in severe renal impairment (CrCl <30 mL/min).
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Clarithromycin may increase the QTc-prolonging activities of Haloperidol."